#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4. Discussion
1-1	0-2	4.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=Here , we show that the primary infection of mice with IDV does not result in disease , as mice demonstrated none of the clinical symptoms associated with the typical progression of IAV infection .
2-1	14-18	Here	_	_	_	_
2-2	19-20	,	_	_	_	_
2-3	21-23	we	person	acc	ana	4-4
2-4	24-28	show	_	_	_	_
2-5	29-33	that	_	_	_	_
2-6	34-37	the	event[3]	new[3]	coref	2-33[12_3]
2-7	38-45	primary	event[3]	new[3]	_	_
2-8	46-55	infection	event[3]	new[3]	_	_
2-9	56-58	of	event[3]	new[3]	_	_
2-10	59-63	mice	event[3]|animal	new[3]|new	coref	2-20
2-11	64-68	with	event[3]	new[3]	_	_
2-12	69-72	IDV	event[3]|object	new[3]|new	coref	3-6
2-13	73-77	does	_	_	_	_
2-14	78-81	not	_	_	_	_
2-15	82-88	result	abstract	new	coref|none	6-4[38_0]|2-15[0_91]
2-16	89-91	in	_	_	_	_
2-17	92-99	disease	abstract	new	coref	7-26
2-18	100-101	,	_	_	_	_
2-19	102-104	as	_	_	_	_
2-20	105-109	mice	animal	giv	coref	4-12[21_0]
2-21	110-122	demonstrated	_	_	_	_
2-22	123-127	none	abstract[8]	new[8]	_	_
2-23	128-130	of	abstract[8]	new[8]	_	_
2-24	131-134	the	abstract[8]|abstract[9]	new[8]|new[9]	coref	7-17[56_9]
2-25	135-143	clinical	abstract[8]|abstract[9]	new[8]|new[9]	_	_
2-26	144-152	symptoms	abstract[8]|abstract[9]	new[8]|new[9]	_	_
2-27	153-163	associated	_	_	_	_
2-28	164-168	with	_	_	_	_
2-29	169-172	the	abstract[10]	new[10]	coref	7-25[59_10]
2-30	173-180	typical	abstract[10]	new[10]	_	_
2-31	181-192	progression	abstract[10]	new[10]	_	_
2-32	193-195	of	abstract[10]	new[10]	_	_
2-33	196-199	IAV	abstract[10]|object|event[12]	new[10]|new|giv[12]	coref|coref	3-4[13_12]|6-27
2-34	200-209	infection	abstract[10]|event[12]	new[10]|giv[12]	_	_
2-35	210-211	.	_	_	_	_

#Text=In addition , infection with IDV did not inhibit bacterial clearance after secondary challenge with S. aureus .
3-1	212-214	In	_	_	_	_
3-2	215-223	addition	_	_	_	_
3-3	224-225	,	_	_	_	_
3-4	226-235	infection	event[13]	giv[13]	coref	5-13[32_13]
3-5	236-240	with	event[13]	giv[13]	_	_
3-6	241-244	IDV	event[13]|object	giv[13]|giv	coref	6-10
3-7	245-248	did	_	_	_	_
3-8	249-252	not	_	_	_	_
3-9	253-260	inhibit	_	_	_	_
3-10	261-270	bacterial	substance|abstract[16]	new|new[16]	coref	4-17
3-11	271-280	clearance	abstract[16]	new[16]	_	_
3-12	281-286	after	_	_	_	_
3-13	287-296	secondary	abstract[17]	new[17]	coref	4-17[24_17]
3-14	297-306	challenge	abstract[17]	new[17]	_	_
3-15	307-311	with	abstract[17]	new[17]	_	_
3-16	312-314	S.	abstract[17]	new[17]	_	_
3-17	315-321	aureus	abstract[17]	new[17]	_	_
3-18	322-323	.	_	_	_	_

#Text=In fact , we found decreased morbidity and increased survival of IDV-infected mice in response to bacterial challenge when compared to mice that were challenged with bacteria alone .
4-1	324-326	In	_	_	_	_
4-2	327-331	fact	_	_	_	_
4-3	332-333	,	_	_	_	_
4-4	334-336	we	person	giv	ana	5-1
4-5	337-342	found	_	_	_	_
4-6	343-352	decreased	abstract[19]	new[19]	coref	9-13[0_19]
4-7	353-362	morbidity	abstract[19]	new[19]	_	_
4-8	363-366	and	_	_	_	_
4-9	367-376	increased	_	_	_	_
4-10	377-385	survival	event[20]	new[20]	_	_
4-11	386-388	of	event[20]	new[20]	_	_
4-12	389-401	IDV-infected	event[20]|animal[21]	new[20]|giv[21]	coref	4-22[0_21]
4-13	402-406	mice	event[20]|animal[21]	new[20]|giv[21]	_	_
4-14	407-409	in	_	_	_	_
4-15	410-418	response	abstract[22]	new[22]	coref	5-30[36_22]
4-16	419-421	to	abstract[22]	new[22]	_	_
4-17	422-431	bacterial	abstract[22]|substance|abstract[24]	new[22]|giv|giv[24]	coref|coref	5-11|18-12[153_24]
4-18	432-441	challenge	abstract[22]|abstract[24]	new[22]|giv[24]	_	_
4-19	442-446	when	_	_	_	_
4-20	447-455	compared	_	_	_	_
4-21	456-458	to	_	_	_	_
4-22	459-463	mice	animal	giv	coref	5-5
4-23	464-468	that	_	_	_	_
4-24	469-473	were	_	_	_	_
4-25	474-484	challenged	_	_	_	_
4-26	485-489	with	_	_	_	_
4-27	490-498	bacteria	substance	new	coref	5-26[35_0]
4-28	499-504	alone	_	_	_	_
4-29	505-506	.	_	_	_	_

#Text=Our findings demonstrate that mice are not susceptible to secondary bacterial infection post-IDV infection and suggest that IDV-mediated anti-viral host responses may help to clear the bacteria by priming a protective inflammatory response .
5-1	507-510	Our	person|abstract[28]	giv|new[28]	ana|coref	6-1|6-23[47_28]
5-2	511-519	findings	abstract[28]	new[28]	_	_
5-3	520-531	demonstrate	_	_	_	_
5-4	532-536	that	_	_	_	_
5-5	537-541	mice	animal	giv	coref	7-7
5-6	542-545	are	_	_	_	_
5-7	546-549	not	_	_	_	_
5-8	550-561	susceptible	_	_	_	_
5-9	562-564	to	_	_	_	_
5-10	565-574	secondary	abstract[31]	new[31]	coref	7-4[51_31]
5-11	575-584	bacterial	object|abstract[31]	giv|new[31]	coref	6-17
5-12	585-594	infection	abstract[31]	new[31]	_	_
5-13	595-603	post-IDV	abstract[31]|event[32]	new[31]|giv[32]	coref	13-22[113_32]
5-14	604-613	infection	abstract[31]|event[32]	new[31]|giv[32]	_	_
5-15	614-617	and	_	_	_	_
5-16	618-625	suggest	_	_	_	_
5-17	626-630	that	_	_	_	_
5-18	631-643	IDV-mediated	abstract[34]	new[34]	coref	21-22[196_34]
5-19	644-654	anti-viral	abstract[34]	new[34]	_	_
5-20	655-659	host	person|abstract[34]	new|new[34]	_	_
5-21	660-669	responses	abstract[34]	new[34]	_	_
5-22	670-673	may	_	_	_	_
5-23	674-678	help	_	_	_	_
5-24	679-681	to	_	_	_	_
5-25	682-687	clear	_	_	_	_
5-26	688-691	the	substance[35]	giv[35]	coref	13-41[120_35]
5-27	692-700	bacteria	substance[35]	giv[35]	_	_
5-28	701-703	by	_	_	_	_
5-29	704-711	priming	_	_	_	_
5-30	712-713	a	abstract[36]	giv[36]	_	_
5-31	714-724	protective	abstract[36]	giv[36]	_	_
5-32	725-737	inflammatory	abstract[36]	giv[36]	_	_
5-33	738-746	response	abstract[36]	giv[36]	_	_
5-34	747-748	.	_	_	_	_

#Text=We will discuss these results in the context of IDV pathogenesis and the regulation of secondary bacterial infections as they compare with our previous findings with IAV .
6-1	749-751	We	person	giv	ana	6-23
6-2	752-756	will	_	_	_	_
6-3	757-764	discuss	_	_	_	_
6-4	765-770	these	abstract[38]	new[38]	coref	7-1[50_38]
6-5	771-778	results	abstract[38]	new[38]	_	_
6-6	779-781	in	_	_	_	_
6-7	782-785	the	abstract[39]	new[39]	_	_
6-8	786-793	context	abstract[39]	new[39]	_	_
6-9	794-796	of	abstract[39]	new[39]	_	_
6-10	797-800	IDV	abstract[39]|object|abstract[41]	new[39]|giv|new[41]	coref	7-9[54_0]
6-11	801-813	pathogenesis	abstract[39]|abstract[41]	new[39]|new[41]	_	_
6-12	814-817	and	abstract[39]	new[39]	_	_
6-13	818-821	the	abstract[39]|event[42]	new[39]|new[42]	_	_
6-14	822-832	regulation	abstract[39]|event[42]	new[39]|new[42]	_	_
6-15	833-835	of	abstract[39]|event[42]	new[39]|new[42]	_	_
6-16	836-845	secondary	abstract[39]|event[42]|abstract[44]	new[39]|new[42]|new[44]	ana	6-20[0_44]
6-17	846-855	bacterial	abstract[39]|event[42]|object|abstract[44]	new[39]|new[42]|giv|new[44]	coref	13-32
6-18	856-866	infections	abstract[39]|event[42]|abstract[44]	new[39]|new[42]|new[44]	_	_
6-19	867-869	as	_	_	_	_
6-20	870-874	they	abstract	giv	coref	11-16[97_0]
6-21	875-882	compare	_	_	_	_
6-22	883-887	with	_	_	_	_
6-23	888-891	our	person|abstract[47]	giv|giv[47]	ana	7-1
6-24	892-900	previous	abstract[47]	giv[47]	_	_
6-25	901-909	findings	abstract[47]	giv[47]	_	_
6-26	910-914	with	abstract[47]	giv[47]	_	_
6-27	915-918	IAV	abstract[47]|abstract	giv[47]|giv	coref	9-22
6-28	919-920	.	_	_	_	_

#Text=Our results demonstrate that infection of mice with OK11 IDV does not cause mice to exhibit the clinical symptoms that are normally associated with influenza disease progression .
7-1	921-924	Our	person|abstract[50]	giv|giv[50]	ana|coref	8-2|9-6[73_50]
7-2	925-932	results	abstract[50]	giv[50]	_	_
7-3	933-944	demonstrate	_	_	_	_
7-4	945-949	that	abstract[51]	giv[51]	coref	8-15[66_51]
7-5	950-959	infection	abstract[51]	giv[51]	_	_
7-6	960-962	of	abstract[51]	giv[51]	_	_
7-7	963-967	mice	abstract[51]|animal	giv[51]|giv	coref	7-14
7-8	968-972	with	_	_	_	_
7-9	973-977	OK11	time|object[54]	new|giv[54]	coref|coref	8-15|10-18[0_54]
7-10	978-981	IDV	object[54]	giv[54]	_	_
7-11	982-986	does	_	_	_	_
7-12	987-990	not	_	_	_	_
7-13	991-996	cause	_	_	_	_
7-14	997-1001	mice	animal	giv	coref	10-13
7-15	1002-1004	to	_	_	_	_
7-16	1005-1012	exhibit	_	_	_	_
7-17	1013-1016	the	abstract[56]	giv[56]	coref	12-20[102_56]
7-18	1017-1025	clinical	abstract[56]	giv[56]	_	_
7-19	1026-1034	symptoms	abstract[56]	giv[56]	_	_
7-20	1035-1039	that	_	_	_	_
7-21	1040-1043	are	_	_	_	_
7-22	1044-1052	normally	_	_	_	_
7-23	1053-1063	associated	_	_	_	_
7-24	1064-1068	with	_	_	_	_
7-25	1069-1078	influenza	abstract|abstract[59]	new|giv[59]	coref	11-17
7-26	1079-1086	disease	abstract|abstract[59]	giv|giv[59]	coref	15-16
7-27	1087-1098	progression	abstract[59]	giv[59]	_	_
7-28	1099-1100	.	_	_	_	_

#Text=Although we did observe the recruitment of lymphocytes and neutrophils to the lung during OK11 infection , we did not observe a decrease in body weight .
8-1	1101-1109	Although	_	_	_	_
8-2	1110-1112	we	person	giv	ana	8-18
8-3	1113-1116	did	_	_	_	_
8-4	1117-1124	observe	_	_	_	_
8-5	1125-1128	the	abstract[61]	new[61]	_	_
8-6	1129-1140	recruitment	abstract[61]	new[61]	_	_
8-7	1141-1143	of	abstract[61]	new[61]	_	_
8-8	1144-1155	lymphocytes	abstract[61]|object	new[61]|new	_	_
8-9	1156-1159	and	abstract[61]	new[61]	_	_
8-10	1160-1171	neutrophils	abstract[61]|abstract	new[61]|new	_	_
8-11	1172-1174	to	_	_	_	_
8-12	1175-1178	the	place[64]	new[64]	_	_
8-13	1179-1183	lung	place[64]	new[64]	_	_
8-14	1184-1190	during	_	_	_	_
8-15	1191-1195	OK11	object|event[66]	giv|giv[66]	coref|coref	10-26[88_66]|17-10
8-16	1196-1205	infection	event[66]	giv[66]	_	_
8-17	1206-1207	,	_	_	_	_
8-18	1208-1210	we	person	giv	ana	9-16
8-19	1211-1214	did	_	_	_	_
8-20	1215-1218	not	_	_	_	_
8-21	1219-1226	observe	_	_	_	_
8-22	1227-1228	a	event[68]	new[68]	coref	10-7[81_68]
8-23	1229-1237	decrease	event[68]	new[68]	_	_
8-24	1238-1240	in	event[68]	new[68]	_	_
8-25	1241-1245	body	event[68]|object|abstract[70]	new[68]|new|new[70]	_	_
8-26	1246-1252	weight	event[68]|abstract[70]	new[68]|new[70]	_	_
8-27	1253-1254	.	_	_	_	_

#Text=Usually , the recruitment of inflammatory cells results in increased signs of morbidity , as we have previously found with other IAV subtypes that induce cellular recruitment .
9-1	1255-1262	Usually	_	_	_	_
9-2	1263-1264	,	_	_	_	_
9-3	1265-1268	the	abstract[71]	new[71]	coref	9-26[79_71]
9-4	1269-1280	recruitment	abstract[71]	new[71]	_	_
9-5	1281-1283	of	abstract[71]	new[71]	_	_
9-6	1284-1296	inflammatory	abstract[71]|abstract[73]	new[71]|giv[73]	coref	11-1[91_73]
9-7	1297-1302	cells	abstract[71]|object|abstract[73]	new[71]|new|giv[73]	_	_
9-8	1303-1310	results	abstract[71]|abstract[73]	new[71]|giv[73]	_	_
9-9	1311-1313	in	abstract[71]|abstract[73]	new[71]|giv[73]	_	_
9-10	1314-1323	increased	abstract[71]|abstract[73]|abstract[74]	new[71]|giv[73]|new[74]	_	_
9-11	1324-1329	signs	abstract[71]|abstract[73]|abstract[74]	new[71]|giv[73]|new[74]	_	_
9-12	1330-1332	of	abstract[71]|abstract[73]|abstract[74]	new[71]|giv[73]|new[74]	_	_
9-13	1333-1342	morbidity	abstract[71]|abstract[73]|abstract[74]|abstract	new[71]|giv[73]|new[74]|giv	coref	13-27
9-14	1343-1344	,	_	_	_	_
9-15	1345-1347	as	_	_	_	_
9-16	1348-1350	we	person	giv	ana	10-3
9-17	1351-1355	have	_	_	_	_
9-18	1356-1366	previously	_	_	_	_
9-19	1367-1372	found	_	_	_	_
9-20	1373-1377	with	_	_	_	_
9-21	1378-1383	other	abstract[78]	new[78]	_	_
9-22	1384-1387	IAV	substance|abstract[78]	giv|new[78]	coref	10-26
9-23	1388-1396	subtypes	abstract[78]	new[78]	_	_
9-24	1397-1401	that	_	_	_	_
9-25	1402-1408	induce	_	_	_	_
9-26	1409-1417	cellular	abstract[79]	giv[79]	_	_
9-27	1418-1429	recruitment	abstract[79]	giv[79]	_	_
9-28	1430-1431	.	_	_	_	_

#Text=Additionally , we did not see a decrease in macrophage levels in mice that were infected with IDV , which is a common observation following IAV infection in C57BL/6 mice .
10-1	1432-1444	Additionally	_	_	_	_
10-2	1445-1446	,	_	_	_	_
10-3	1447-1449	we	person	giv	ana	13-6
10-4	1450-1453	did	_	_	_	_
10-5	1454-1457	not	_	_	_	_
10-6	1458-1461	see	_	_	_	_
10-7	1462-1463	a	event[81]	giv[81]	_	_
10-8	1464-1472	decrease	event[81]	giv[81]	_	_
10-9	1473-1475	in	event[81]	giv[81]	_	_
10-10	1476-1486	macrophage	event[81]|place|abstract[83]	giv[81]|new|new[83]	coref	20-14
10-11	1487-1493	levels	event[81]|abstract[83]	giv[81]|new[83]	_	_
10-12	1494-1496	in	event[81]|abstract[83]	giv[81]|new[83]	_	_
10-13	1497-1501	mice	event[81]|abstract[83]|animal	giv[81]|new[83]|giv	coref	10-29[90_0]
10-14	1502-1506	that	_	_	_	_
10-15	1507-1511	were	_	_	_	_
10-16	1512-1520	infected	_	_	_	_
10-17	1521-1525	with	_	_	_	_
10-18	1526-1529	IDV	abstract	giv	coref	11-9
10-19	1530-1531	,	_	_	_	_
10-20	1532-1537	which	_	_	_	_
10-21	1538-1540	is	_	_	_	_
10-22	1541-1542	a	abstract[86]	new[86]	_	_
10-23	1543-1549	common	abstract[86]	new[86]	_	_
10-24	1550-1561	observation	abstract[86]	new[86]	_	_
10-25	1562-1571	following	_	_	_	_
10-26	1572-1575	IAV	object|event[88]	giv|giv[88]	coref|coref	11-9[94_88]|12-27
10-27	1576-1585	infection	event[88]	giv[88]	_	_
10-28	1586-1588	in	event[88]	giv[88]	_	_
10-29	1589-1596	C57BL/6	event[88]|animal|animal[90]	giv[88]|new|giv[90]	coref|coref	13-18[0_90]|19-6
10-30	1597-1601	mice	event[88]|animal[90]	giv[88]|giv[90]	_	_
10-31	1602-1603	.	_	_	_	_

#Text=These results indicate that the inflammatory environment during IDV infection is subdued when compared to other influenza virus infections .
11-1	1604-1609	These	abstract[91]	giv[91]	_	_
11-2	1610-1617	results	abstract[91]	giv[91]	_	_
11-3	1618-1626	indicate	_	_	_	_
11-4	1627-1631	that	_	_	_	_
11-5	1632-1635	the	abstract[92]	new[92]	_	_
11-6	1636-1648	inflammatory	abstract[92]	new[92]	_	_
11-7	1649-1660	environment	abstract[92]	new[92]	_	_
11-8	1661-1667	during	abstract[92]	new[92]	_	_
11-9	1668-1671	IDV	abstract[92]|object|event[94]	new[92]|giv|giv[94]	coref|coref	12-27[104_94]|14-15
11-10	1672-1681	infection	abstract[92]|event[94]	new[92]|giv[94]	_	_
11-11	1682-1684	is	_	_	_	_
11-12	1685-1692	subdued	_	_	_	_
11-13	1693-1697	when	_	_	_	_
11-14	1698-1706	compared	_	_	_	_
11-15	1707-1709	to	_	_	_	_
11-16	1710-1715	other	abstract[97]	giv[97]	_	_
11-17	1716-1725	influenza	abstract|abstract[97]	giv|giv[97]	_	_
11-18	1726-1731	virus	abstract|abstract[97]	new|giv[97]	_	_
11-19	1732-1742	infections	abstract[97]	giv[97]	_	_
11-20	1743-1744	.	_	_	_	_

#Text=Specifically , the high level of macrophages that are still present at day 7 post-OK11 may aid in preventing the clinical symptoms that were observed after IAV infection .
12-1	1745-1757	Specifically	_	_	_	_
12-2	1758-1759	,	_	_	_	_
12-3	1760-1763	the	quantity[98]	new[98]	_	_
12-4	1764-1768	high	quantity[98]	new[98]	_	_
12-5	1769-1774	level	quantity[98]	new[98]	_	_
12-6	1775-1777	of	quantity[98]	new[98]	_	_
12-7	1778-1789	macrophages	quantity[98]|object	new[98]|new	coref	17-27
12-8	1790-1794	that	_	_	_	_
12-9	1795-1798	are	_	_	_	_
12-10	1799-1804	still	_	_	_	_
12-11	1805-1812	present	_	_	_	_
12-12	1813-1815	at	_	_	_	_
12-13	1816-1819	day	time	new	_	_
12-14	1820-1821	7	time[101]	new[101]	_	_
12-15	1822-1831	post-OK11	time[101]	new[101]	_	_
12-16	1832-1835	may	_	_	_	_
12-17	1836-1839	aid	_	_	_	_
12-18	1840-1842	in	_	_	_	_
12-19	1843-1853	preventing	_	_	_	_
12-20	1854-1857	the	abstract[102]	giv[102]	_	_
12-21	1858-1866	clinical	abstract[102]	giv[102]	_	_
12-22	1867-1875	symptoms	abstract[102]	giv[102]	_	_
12-23	1876-1880	that	_	_	_	_
12-24	1881-1885	were	_	_	_	_
12-25	1886-1894	observed	_	_	_	_
12-26	1895-1900	after	_	_	_	_
12-27	1901-1904	IAV	object|event[104]	giv|giv[104]	coref|coref	13-10[0_104]|13-16
12-28	1905-1914	infection	event[104]	giv[104]	_	_
12-29	1915-1916	.	_	_	_	_

#Text=Similar to other groups , we have previously investigated infection by the PR8 strain of IAV in mice and demonstrated that primary PR8 infection can increase morbidity and mortality of secondary bacterial infection as compared to infection of mice with bacteria alone .
13-1	1917-1924	Similar	_	_	_	_
13-2	1925-1927	to	_	_	_	_
13-3	1928-1933	other	person[105]	new[105]	_	_
13-4	1934-1940	groups	person[105]	new[105]	_	_
13-5	1941-1942	,	_	_	_	_
13-6	1943-1945	we	person	giv	ana	14-5
13-7	1946-1950	have	_	_	_	_
13-8	1951-1961	previously	_	_	_	_
13-9	1962-1974	investigated	_	_	_	_
13-10	1975-1984	infection	event	giv	coref	13-31[117_0]
13-11	1985-1987	by	_	_	_	_
13-12	1988-1991	the	abstract[109]	new[109]	_	_
13-13	1992-1995	PR8	abstract|abstract[109]	new|new[109]	coref	13-23
13-14	1996-2002	strain	abstract[109]	new[109]	_	_
13-15	2003-2005	of	abstract[109]	new[109]	_	_
13-16	2006-2009	IAV	abstract[109]|object	new[109]|giv	coref	19-19
13-17	2010-2012	in	abstract[109]	new[109]	_	_
13-18	2013-2017	mice	abstract[109]|animal	new[109]|giv	coref	13-39
13-19	2018-2021	and	_	_	_	_
13-20	2022-2034	demonstrated	_	_	_	_
13-21	2035-2039	that	_	_	_	_
13-22	2040-2047	primary	event[113]	giv[113]	_	_
13-23	2048-2051	PR8	object|event[113]	giv|giv[113]	_	_
13-24	2052-2061	infection	event[113]	giv[113]	_	_
13-25	2062-2065	can	_	_	_	_
13-26	2066-2074	increase	_	_	_	_
13-27	2075-2084	morbidity	abstract	giv	_	_
13-28	2085-2088	and	_	_	_	_
13-29	2089-2098	mortality	event[115]	new[115]	coref	15-22[0_115]
13-30	2099-2101	of	event[115]	new[115]	_	_
13-31	2102-2111	secondary	event[115]|abstract[117]	new[115]|giv[117]	coref	14-18[126_117]
13-32	2112-2121	bacterial	event[115]|object|abstract[117]	new[115]|giv|giv[117]	coref	16-14
13-33	2122-2131	infection	event[115]|abstract[117]	new[115]|giv[117]	_	_
13-34	2132-2134	as	_	_	_	_
13-35	2135-2143	compared	_	_	_	_
13-36	2144-2146	to	_	_	_	_
13-37	2147-2156	infection	event[118]	new[118]	coref	14-14[125_118]
13-38	2157-2159	of	event[118]	new[118]	_	_
13-39	2160-2164	mice	event[118]|animal	new[118]|giv	coref	14-27
13-40	2165-2169	with	event[118]	new[118]	_	_
13-41	2170-2178	bacteria	event[118]|substance[120]	new[118]|giv[120]	coref	14-30[0_120]
13-42	2179-2184	alone	event[118]|substance[120]	new[118]|giv[120]	_	_
13-43	2185-2186	.	_	_	_	_

#Text=In this study , we demonstrate that there is a protective effect of primary IDV infection during secondary S. aureus infection that is not observed in mice infected with bacteria alone .
14-1	2187-2189	In	_	_	_	_
14-2	2190-2194	this	abstract[121]	new[121]	_	_
14-3	2195-2200	study	abstract[121]	new[121]	_	_
14-4	2201-2202	,	_	_	_	_
14-5	2203-2205	we	person	giv	ana	17-3
14-6	2206-2217	demonstrate	_	_	_	_
14-7	2218-2222	that	_	_	_	_
14-8	2223-2228	there	_	_	_	_
14-9	2229-2231	is	_	_	_	_
14-10	2232-2233	a	abstract[123]	new[123]	_	_
14-11	2234-2244	protective	abstract[123]	new[123]	_	_
14-12	2245-2251	effect	abstract[123]	new[123]	_	_
14-13	2252-2254	of	abstract[123]	new[123]	_	_
14-14	2255-2262	primary	abstract[123]|event[125]	new[123]|giv[125]	_	_
14-15	2263-2266	IDV	abstract[123]|substance|event[125]	new[123]|giv|giv[125]	coref	16-4
14-16	2267-2276	infection	abstract[123]|event[125]	new[123]|giv[125]	_	_
14-17	2277-2283	during	abstract[123]|event[125]	new[123]|giv[125]	_	_
14-18	2284-2293	secondary	abstract[123]|event[125]|abstract[126]	new[123]|giv[125]|giv[126]	coref	16-13[140_126]
14-19	2294-2296	S.	abstract[123]|event[125]|abstract[126]	new[123]|giv[125]|giv[126]	_	_
14-20	2297-2303	aureus	abstract[123]|event[125]|abstract[126]	new[123]|giv[125]|giv[126]	_	_
14-21	2304-2313	infection	abstract[123]|event[125]|abstract[126]	new[123]|giv[125]|giv[126]	_	_
14-22	2314-2318	that	_	_	_	_
14-23	2319-2321	is	_	_	_	_
14-24	2322-2325	not	_	_	_	_
14-25	2326-2334	observed	_	_	_	_
14-26	2335-2337	in	_	_	_	_
14-27	2338-2342	mice	animal	giv	coref	15-3[129_0]
14-28	2343-2351	infected	_	_	_	_
14-29	2352-2356	with	_	_	_	_
14-30	2357-2365	bacteria	substance	giv	_	_
14-31	2366-2371	alone	_	_	_	_
14-32	2372-2373	.	_	_	_	_

#Text=Specifically , OK11-infected mice challenged with S. aureus were less susceptible to clinical signs of disease ( weight loss ) and mortality when compared to mice that received S. aureus alone .
15-1	2374-2386	Specifically	_	_	_	_
15-2	2387-2388	,	_	_	_	_
15-3	2389-2402	OK11-infected	animal[129]	giv[129]	coref	15-26[0_129]
15-4	2403-2407	mice	animal[129]	giv[129]	_	_
15-5	2408-2418	challenged	_	_	_	_
15-6	2419-2423	with	_	_	_	_
15-7	2424-2426	S.	person	new	_	_
15-8	2427-2433	aureus	_	_	_	_
15-9	2434-2438	were	_	_	_	_
15-10	2439-2443	less	_	_	_	_
15-11	2444-2455	susceptible	_	_	_	_
15-12	2456-2458	to	_	_	_	_
15-13	2459-2467	clinical	abstract[131]	new[131]	_	_
15-14	2468-2473	signs	abstract[131]	new[131]	_	_
15-15	2474-2476	of	abstract[131]	new[131]	_	_
15-16	2477-2484	disease	abstract[131]|abstract	new[131]|giv	appos	15-18[133_0]
15-17	2485-2486	(	_	_	_	_
15-18	2487-2493	weight	abstract[133]	giv[133]	_	_
15-19	2494-2498	loss	abstract[133]	giv[133]	_	_
15-20	2499-2500	)	_	_	_	_
15-21	2501-2504	and	_	_	_	_
15-22	2505-2514	mortality	event	giv	ana	16-1
15-23	2515-2519	when	_	_	_	_
15-24	2520-2528	compared	_	_	_	_
15-25	2529-2531	to	_	_	_	_
15-26	2532-2536	mice	animal	giv	coref	17-18[146_0]
15-27	2537-2541	that	_	_	_	_
15-28	2542-2550	received	_	_	_	_
15-29	2551-2553	S.	_	_	_	_
15-30	2554-2560	aureus	_	_	_	_
15-31	2561-2566	alone	_	_	_	_
15-32	2567-2568	.	_	_	_	_

#Text=This suggests that IDV induces host anti-viral mechanisms that are protective against secondary bacterial infection .
16-1	2569-2573	This	event	giv	_	_
16-2	2574-2582	suggests	_	_	_	_
16-3	2583-2587	that	_	_	_	_
16-4	2588-2591	IDV	object	giv	coref	21-15
16-5	2592-2599	induces	_	_	_	_
16-6	2600-2604	host	_	_	_	_
16-7	2605-2615	anti-viral	abstract[138]	new[138]	_	_
16-8	2616-2626	mechanisms	abstract[138]	new[138]	_	_
16-9	2627-2631	that	_	_	_	_
16-10	2632-2635	are	_	_	_	_
16-11	2636-2646	protective	_	_	_	_
16-12	2647-2654	against	_	_	_	_
16-13	2655-2664	secondary	abstract[140]	giv[140]	coref	17-10[143_140]
16-14	2665-2674	bacterial	object|abstract[140]	giv|giv[140]	coref	17-15
16-15	2675-2684	infection	abstract[140]	giv[140]	_	_
16-16	2685-2686	.	_	_	_	_

#Text=Interestingly , we found that , in addition to OK11 infection alone , secondary bacterial infection of OK11-infected mice also does not decrease the level of macrophages .
17-1	2687-2700	Interestingly	_	_	_	_
17-2	2701-2702	,	_	_	_	_
17-3	2703-2705	we	person	giv	ana	19-1
17-4	2706-2711	found	_	_	_	_
17-5	2712-2716	that	_	_	_	_
17-6	2717-2718	,	_	_	_	_
17-7	2719-2721	in	_	_	_	_
17-8	2722-2730	addition	_	_	_	_
17-9	2731-2733	to	_	_	_	_
17-10	2734-2738	OK11	object|event[143]	giv|giv[143]	ana	18-1[0_143]
17-11	2739-2748	infection	event[143]	giv[143]	_	_
17-12	2749-2754	alone	event[143]	giv[143]	_	_
17-13	2755-2756	,	_	_	_	_
17-14	2757-2766	secondary	abstract[145]	new[145]	_	_
17-15	2767-2776	bacterial	object|abstract[145]	giv|new[145]	coref	18-13
17-16	2777-2786	infection	abstract[145]	new[145]	_	_
17-17	2787-2789	of	abstract[145]	new[145]	_	_
17-18	2790-2803	OK11-infected	abstract[145]|animal[146]	new[145]|giv[146]	coref	19-6[158_146]
17-19	2804-2808	mice	abstract[145]|animal[146]	new[145]|giv[146]	_	_
17-20	2809-2813	also	_	_	_	_
17-21	2814-2818	does	_	_	_	_
17-22	2819-2822	not	_	_	_	_
17-23	2823-2831	decrease	_	_	_	_
17-24	2832-2835	the	abstract[147]	new[147]	_	_
17-25	2836-2841	level	abstract[147]	new[147]	_	_
17-26	2842-2844	of	abstract[147]	new[147]	_	_
17-27	2845-2856	macrophages	abstract[147]|object	new[147]|giv	coref	18-4
17-28	2857-2858	.	_	_	_	_

#Text=This suggests that macrophages may be involved in mediating protection from secondary bacterial challenge .
18-1	2859-2863	This	event	giv	coref	19-19[162_0]
18-2	2864-2872	suggests	_	_	_	_
18-3	2873-2877	that	_	_	_	_
18-4	2878-2889	macrophages	object	giv	coref	19-10[159_0]
18-5	2890-2893	may	_	_	_	_
18-6	2894-2896	be	_	_	_	_
18-7	2897-2905	involved	_	_	_	_
18-8	2906-2908	in	_	_	_	_
18-9	2909-2918	mediating	_	_	_	_
18-10	2919-2929	protection	abstract	new	coref	21-30[198_0]
18-11	2930-2934	from	_	_	_	_
18-12	2935-2944	secondary	abstract[153]	giv[153]	_	_
18-13	2945-2954	bacterial	substance|abstract[153]	giv|giv[153]	coref	19-31
18-14	2955-2964	challenge	abstract[153]	giv[153]	_	_
18-15	2965-2966	.	_	_	_	_

#Text=Our previous work with PR8-infected C57BL/6 mice showed that protective alveolar macrophages are depleted over the course of IAV infection and replaced by damaging inflammatory monocytes/neutrophils that contribute to secondary bacterial susceptibility .
19-1	2967-2970	Our	person|abstract[155]	giv|new[155]	ana	20-43
19-2	2971-2979	previous	abstract[155]	new[155]	_	_
19-3	2980-2984	work	abstract[155]	new[155]	_	_
19-4	2985-2989	with	abstract[155]	new[155]	_	_
19-5	2990-3002	PR8-infected	abstract[155]|abstract	new[155]|new	_	_
19-6	3003-3010	C57BL/6	abstract[155]|animal|animal[158]	new[155]|giv|giv[158]	coref|coref	20-22|20-22[175_158]
19-7	3011-3015	mice	abstract[155]|animal[158]	new[155]|giv[158]	_	_
19-8	3016-3022	showed	_	_	_	_
19-9	3023-3027	that	_	_	_	_
19-10	3028-3038	protective	object[159]	giv[159]	coref	21-27[0_159]
19-11	3039-3047	alveolar	object[159]	giv[159]	_	_
19-12	3048-3059	macrophages	object[159]	giv[159]	_	_
19-13	3060-3063	are	_	_	_	_
19-14	3064-3072	depleted	_	_	_	_
19-15	3073-3077	over	_	_	_	_
19-16	3078-3081	the	time[160]	new[160]	_	_
19-17	3082-3088	course	time[160]	new[160]	_	_
19-18	3089-3091	of	time[160]	new[160]	_	_
19-19	3092-3095	IAV	time[160]|object|event[162]	new[160]|giv|giv[162]	coref|coref	20-28|20-38[180_162]
19-20	3096-3105	infection	time[160]|event[162]	new[160]|giv[162]	_	_
19-21	3106-3109	and	_	_	_	_
19-22	3110-3118	replaced	_	_	_	_
19-23	3119-3121	by	_	_	_	_
19-24	3122-3130	damaging	_	_	_	_
19-25	3131-3143	inflammatory	object[163]	new[163]	_	_
19-26	3144-3165	monocytes/neutrophils	object[163]	new[163]	_	_
19-27	3166-3170	that	_	_	_	_
19-28	3171-3181	contribute	_	_	_	_
19-29	3182-3184	to	_	_	_	_
19-30	3185-3194	secondary	abstract[165]	new[165]	coref	20-35[178_165]
19-31	3195-3204	bacterial	substance|abstract[165]	giv|new[165]	coref	20-39
19-32	3205-3219	susceptibility	abstract[165]	new[165]	_	_
19-33	3220-3221	.	_	_	_	_

#Text=However , Califano , Furuya , and Metzger ( 2013 ) demonstrated that macrophage dysfunction , rather than depletion , in C57BL/6 mice that were infected with IAV is a factor that contributes to increased susceptibility to secondary bacterial infection , and our previous PR8-infected mouse data supports this .
20-1	3222-3229	However	_	_	_	_
20-2	3230-3231	,	_	_	_	_
20-3	3232-3240	Califano	person|person[167]	new|new[167]	ana	21-20[0_167]
20-4	3241-3242	,	person[167]	new[167]	_	_
20-5	3243-3249	Furuya	person[167]|person	new[167]|new	_	_
20-6	3250-3251	,	person[167]	new[167]	_	_
20-7	3252-3255	and	person[167]	new[167]	_	_
20-8	3256-3263	Metzger	person[167]|person[169]	new[167]|new[169]	_	_
20-9	3264-3265	(	person[167]|person[169]	new[167]|new[169]	_	_
20-10	3266-3270	2013	person[167]|person[169]|time	new[167]|new[169]|new	_	_
20-11	3271-3272	)	person[167]|person[169]	new[167]|new[169]	_	_
20-12	3273-3285	demonstrated	_	_	_	_
20-13	3286-3290	that	_	_	_	_
20-14	3291-3301	macrophage	abstract|abstract[172]	giv|new[172]	coref|coref	20-30[177_172]|21-8
20-15	3302-3313	dysfunction	abstract[172]	new[172]	_	_
20-16	3314-3315	,	abstract[172]	new[172]	_	_
20-17	3316-3322	rather	abstract[172]|event[173]	new[172]|new[173]	ana	20-49[0_173]
20-18	3323-3327	than	abstract[172]|event[173]	new[172]|new[173]	_	_
20-19	3328-3337	depletion	abstract[172]|event[173]	new[172]|new[173]	_	_
20-20	3338-3339	,	abstract[172]	new[172]	_	_
20-21	3340-3342	in	abstract[172]	new[172]	_	_
20-22	3343-3350	C57BL/6	abstract[172]|animal|animal[175]	new[172]|giv|giv[175]	_	_
20-23	3351-3355	mice	abstract[172]|animal[175]	new[172]|giv[175]	_	_
20-24	3356-3360	that	_	_	_	_
20-25	3361-3365	were	_	_	_	_
20-26	3366-3374	infected	_	_	_	_
20-27	3375-3379	with	_	_	_	_
20-28	3380-3383	IAV	abstract	giv	coref	21-22
20-29	3384-3386	is	_	_	_	_
20-30	3387-3388	a	abstract[177]	giv[177]	_	_
20-31	3389-3395	factor	abstract[177]	giv[177]	_	_
20-32	3396-3400	that	_	_	_	_
20-33	3401-3412	contributes	_	_	_	_
20-34	3413-3415	to	_	_	_	_
20-35	3416-3425	increased	abstract[178]	giv[178]	_	_
20-36	3426-3440	susceptibility	abstract[178]	giv[178]	_	_
20-37	3441-3443	to	abstract[178]	giv[178]	_	_
20-38	3444-3453	secondary	abstract[178]|abstract[180]	giv[178]|giv[180]	coref	21-15[192_180]
20-39	3454-3463	bacterial	abstract[178]|object|abstract[180]	giv[178]|giv|giv[180]	coref	21-34
20-40	3464-3473	infection	abstract[178]|abstract[180]	giv[178]|giv[180]	_	_
20-41	3474-3475	,	_	_	_	_
20-42	3476-3479	and	_	_	_	_
20-43	3480-3483	our	person|abstract[183]	giv|new[183]	_	_
20-44	3484-3492	previous	abstract[183]	new[183]	_	_
20-45	3493-3505	PR8-infected	abstract[183]	new[183]	_	_
20-46	3506-3511	mouse	animal|abstract[183]	new|new[183]	_	_
20-47	3512-3516	data	abstract[183]	new[183]	_	_
20-48	3517-3525	supports	_	_	_	_
20-49	3526-3530	this	event	giv	_	_
20-50	3531-3532	.	_	_	_	_

#Text=It will be important to determine the macrophage phenotypic properties over the course of IDV infection , and compare them with IAV responses to define how macrophages contribute to this protection from secondary bacterial infection .
21-1	3533-3535	It	abstract	new	cata	21-1[0_186]
21-2	3536-3540	will	_	_	_	_
21-3	3541-3543	be	_	_	_	_
21-4	3544-3553	important	_	_	_	_
21-5	3554-3556	to	abstract[186]	new[186]	_	_
21-6	3557-3566	determine	abstract[186]	new[186]	_	_
21-7	3567-3570	the	abstract[186]|abstract[189]	new[186]|new[189]	_	_
21-8	3571-3581	macrophage	abstract[186]|place|abstract[189]	new[186]|giv|new[189]	_	_
21-9	3582-3592	phenotypic	abstract[186]|abstract|abstract[189]	new[186]|new|new[189]	_	_
21-10	3593-3603	properties	abstract[186]|abstract[189]	new[186]|new[189]	_	_
21-11	3604-3608	over	_	_	_	_
21-12	3609-3612	the	abstract[190]	new[190]	_	_
21-13	3613-3619	course	abstract[190]	new[190]	_	_
21-14	3620-3622	of	abstract[190]	new[190]	_	_
21-15	3623-3626	IDV	abstract[190]|event|event[192]	new[190]|giv|giv[192]	coref	21-33[200_192]
21-16	3627-3636	infection	abstract[190]|event[192]	new[190]|giv[192]	_	_
21-17	3637-3638	,	_	_	_	_
21-18	3639-3642	and	_	_	_	_
21-19	3643-3650	compare	abstract[193]	new[193]	_	_
21-20	3651-3655	them	abstract[193]|person	new[193]|giv	_	_
21-21	3656-3660	with	_	_	_	_
21-22	3661-3664	IAV	abstract|abstract[196]	giv|giv[196]	_	_
21-23	3665-3674	responses	abstract[196]	giv[196]	_	_
21-24	3675-3677	to	_	_	_	_
21-25	3678-3684	define	_	_	_	_
21-26	3685-3688	how	_	_	_	_
21-27	3689-3700	macrophages	object	giv	_	_
21-28	3701-3711	contribute	_	_	_	_
21-29	3712-3714	to	_	_	_	_
21-30	3715-3719	this	abstract[198]	giv[198]	_	_
21-31	3720-3730	protection	abstract[198]	giv[198]	_	_
21-32	3731-3735	from	_	_	_	_
21-33	3736-3745	secondary	abstract[200]	giv[200]	_	_
21-34	3746-3755	bacterial	object|abstract[200]	giv|giv[200]	_	_
21-35	3756-3765	infection	abstract[200]	giv[200]	_	_
21-36	3766-3767	.	_	_	_	_
